nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.06.2007 | Original Paper

Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells

verfasst von: P. Kanagaraj, M. R. Vijayababu, B. Ravisankar, J. Anbalagan, M. M. Aruldhas, J. Arunakaran

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Prostate cancer is the second most common cancer that leads to death in elderly men. The risk of prostate cancer prevalence is often associated with the elevated level of insulin-like growth factor-I (IGF-I) and decreased level of IGF-binding protein 3 (IGFBP-3). Lycopene, a carotenoid, reduces the proliferation of cancer cells and induces apoptosis. Hence, higher intake of lycopene can be associated with the lower risk of prostate cancer. However, the mechanism of action of lycopene in the prevention of prostate cancer is still unclear. The present study was carried out to study the effects of lycopene on the components of IGF system and apoptosis in androgen-independent prostate cancer cells (PC-3 cells).

Methods

PC-3 cells were treated with various concentrations of lycopene, (20, 40 and 60 μM) for 24, 48, 72 and 96 h. IGF-I, IGFBP-3 and IGF-I receptor (IGF-IR) levels in lycopene-treated cells were evaluated. Annexin V and propidium iodide (PI) binding studies were done to assess apoptosis.

Results

PC-3 cells treated with lycopene showed a significant decrease in cell proliferation. Lycopene, at a dose of 40 μM, significantly increased the level of IGFBP-3. Lycopene-induced apoptosis was confirmed by annexin V and PI binding. Lycopene-induced DNA fragmentation was absent after 24 h treatment whereas the same was observed after 48 h treatment. There was a significant decrease in the IGF-IR expression after the cells were treated with lycopene and IGF-I.

Conclusion

The data obtained suggest that the components of the IGF system may act as a positive regulator of lycopene-induced apoptosis in PC-3 cells. Thus, the observed lycopene-induced biological effects and their associated mechanisms are encouraging and may lead to the development of a highly successful drug for the treatment of prostate cancer.

Angelloz-Nicoud P, Binoux M (1995) Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 136:5485–5492PubMedCrossRef

Chan M, Stampfer J, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563–566PubMedCrossRef

Chaudhary KS, Abel PD, Stamp GWH, Lalani E (2001) Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl-2 transfected DU145 prostatic cancer cells. J Pathol 193:522–529PubMedCrossRef

Gerster H (1997) The potential role of lycopene for human health. J Am Coll Nutr 16:109–126PubMed

Giovannucci E (2002) A review of epidemiologic studies of tomatoes, lycopene, and prostate cancer. Exp Biol Med 227:852–859

Hall AK (1996) Liarozole amplifies retinoid-induced apoptosis in human prostate cells. Anticancer Drugs 7:312–320PubMedCrossRef

Hantz HL, Young LF, Martin KR (2005) Physiologically attainable concentration of lycopene induced mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp Biol Med 2030:171–179

Huynh H, Yang X, Pollak M (1996) Estradiol and anti-estrogens regulate a growth inhibitory insulin-like growth factor binding protein-3 autocrine loop in human breast cancer cells. J Biol Chem 271:1061–1021CrossRef

Huynh H, Pollak M, Zhang JC (1998) Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)₂D₃ and its analog EB1089. Int J Oncol 13:137–143PubMed

Hwang ES, Bowen PE (2005) Effects of tomato paste extracts on cell proliferation, cell-cycle arrest and apoptosis in LNCaP human prostate cancer cells. Biofactors 23:75–84PubMed

Iwamura M, Sluss PM, Casamento JB, Cockett AT (1993) Insulin-like growth factor-I: action and receptor characterization in human prostate cell lines. Prostate 22:243–252PubMedCrossRef

Kaicer E, Blat C, Harel L (1991) IGF-I and IGF binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. Growth Factors 4:231–237PubMed

Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16–23PubMed

Karas M, Amir H, Fishman D, Danilenko M, Segal S, Nahum A, Koifmann A, Giat Y, Levy J, Sharoni Y (2000) Lycopene interfere with cell cycle progression and insulin-like growth factor-I signaling in mammary cancer. Nutr Cancer 36:101–111PubMedCrossRef

Kelin RD, Fischer SM (2002) Black tea polyphenols inhits IGF-I induced signal pathway through Akt in normal prostate epithelial cells and DU 145 prostate carcinoma cells. Carcinogenesis 23:217–221CrossRef

Kim L, Rao AV, Rao LG (2002) Effect of lycopene on prostate LNCaP cancer cells in culture. J Med Food 5:181–187PubMedCrossRef

Kimura G, Kasuva J, Giannini S, Honda Y, Mohan S, Kawachi M, Akimoto M, Fujita-Yamaguchi Y (1996) Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int J Urol 3:39–46PubMed

Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH (1994) Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415–1420PubMed

Kotake-Nara E, Kushiro M, Zhang H, Sugawara T, Miyashita K, Nagao A (2001) Carotenoids affect proliferation of human prostate cells. J Nutr 131:3303–3306PubMed

Kotake-Nara E, Kim SJ, Kobori M, Miyashita K, Nagao A (2002) Acyclo-retinoic acid induces apoptosis in human prostate cancer cells. Anticancer Res 22:689–695PubMed

Liu C, Lian F, Smith DE, Russell RM, Wang XD (2003) Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed Ferrets. Cancer Res 63:3138–3144PubMed

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275PubMed

Miles LEM, Lipschitz DA, Bieber CP, Cook JD (1974) Measurement of serum ferritin by a 2-site immunoradiometric assay. Anal Biochem 61:209–224PubMedCrossRef

Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 16:55–63CrossRef

Newling DW (1996a) Anti-androgens in the treatment of prostate cancer. Br J Urol 7:776–784

Newling DW (1996b) The management of hormone refractory prostate cancer. Eur Urol 29:69–74

Park YO, Hwang ES, Moon TW (2005) The effect of lycopene on cell growth and oxidative DNA damage of Hep3B human hepatoma cells. Biofactors 23:129–139PubMed

Pastori M, Pfander H, Boscoboinik D, Azzi A (1998) Lycopene in association with alpha-tocopherol inhibits at physiological concentrations proliferation of prostate carcinoma cells. Biochem Biophys Res Commun 250:582–585PubMedCrossRef

Pietrzkowski Z, Mulholland G, Goomella L, Jameson BA, Wernicke D, Baserga B (1993) Inhibition of growth of prostate cancer cell lines by peptide analogue of insulin-like growth factor I. Cancer Res 53:1102–1106PubMed

Rajah R, Valentinis B, Cohen P (1997) Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53 and IGF-independent mechanism. J Biol Chem 272:12181–12188PubMedCrossRef

Rajah R, Khare A, Lee PD, Cohen P (1999) Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. J Endocrinol 163:487–494PubMedCrossRef

Scher HI, Steineck G, Kelly WK (1995) Hormone refractory (D3) prostate cancer: refining the concept. Urology 46:142–148PubMedCrossRef

Tang L, Jin T, Zeng X, Wang JS (2005) Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in BALB/c nude mice. J Nutr 135:287–290PubMed

Vainas IG (2001) Octreotide in the management of hormone-refractory prostate cancer. Chemotherapy 47:109–129PubMedCrossRef

Vijayababu MR, Kanagaraj P, Arunkumar A, Ilangovan R, Aruldhas MM, Arunakaran J (2005) Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. J Cancer Res Clin Oncol 131:765–771PubMedCrossRef

Vijayababu MR, Kanagaraj P, Arunkumar A, Ilanagovan R, Dharmarajan A, Arunakaran J (2006) Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2 related proteins: a possible mediation by IGFBP-3. Oncol Res 16:67–74PubMed

Wetterau LA, Francis MJ, Ma L, Cohen P (2003) Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells. J Clin Endocrinol Metab 88:3354–3359PubMedCrossRef

Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D (1998) Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 17:911–915CrossRef

Zhang J, Jung K, Lein M, Kristiansen G, Rudolph B, Hauptmann S, Schnorr D, Loening SA, Lichtinghagen R (2002) Differential expression of matrix metalloproteinases and their tissue inhibitors. Prostate 50:38–45PubMedCrossRef

Zi X, Zhang J, Agarwal R, Pollak M (2000) Silibinin up-regulates insulin-like growth factor-binding protein-3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60:5617–5620PubMed

Titel: Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells
verfasst von: P. Kanagaraj
M. R. Vijayababu
B. Ravisankar
J. Anbalagan
M. M. Aruldhas
J. Arunakaran
Publikationsdatum: 01.06.2007
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2007
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-006-0177-6

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations

MYH mutations are rare in prostate cancer

Distinct reconstitution of neutrophil functions after allogeneic peripheral blood stem cell transplantation

Clinical significance of aromatase protein expression in axillary node negative breast cancer

A glycoproteome database of normal human liver tissue

Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie